First and Only Generic Fluticasone Propionate and Salmeterol (ICS/LABA) Inhaler Available in the U.S.

Size: px
Start display at page:

Download "First and Only Generic Fluticasone Propionate and Salmeterol (ICS/LABA) Inhaler Available in the U.S."

Transcription

1 Teva Launches AirDu RespiClick and its Authrized Generic, Tw Inhalers Cntaining Fluticasne Prpinate and Salmeterl First and Only Generic Fluticasne Prpinate and Salmeterl (ICS/LABA) Inhaler Available in the U.S. JERUSALEM, April 20, 2017 Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) tday annunced the simultaneus launch f AirDu RespiClick (fluticasne prpinate and salmeterl) inhalatin pwder and its authrized generic fr the treatment f asthma in patients aged 12 years and lder wh are uncntrlled n an inhaled crticsterid (ICS) r whse disease severity clearly warrants the use f an ICS/lng-acting beta 2 -adrenergic agnist (LABA) cmbinatin. AirDu RespiClick and its authrized generic are fixed-dse cmbinatin asthma therapies cntaining an ICS and a LABA, the same active ingredients as Advair. The authrized generic is knwn as fluticasne prpinate and salmeterl inhalatin pwder (multidse dry pwder inhaler). Teva is launching bth prducts at the same time in an effrt t address the need fr mre affrdable asthma treatment ptins in the U.S. Teva expects that sales f the authrized generic will represent mst f the sales f the tw prducts. With the launch f AirDu RespiClick and its authrized generic, ur intent is t meet the needs f patients, prviders, and payers in the U.S. seeking greater access t lwer-cst asthma inhaler technlgy, while als allwing Teva t cmpete in the highly cmpetitive asthma cmbinatin cntrller market, said Rb Kremans, M.D., President and CEO f Glbal Specialty Medicines at Teva. This imprtant launch marks nt nly the first available generic ICS/LABA prduct in the U.S., but als the cntinued expansin f ur RespiClick family f prducts, which nw includes breath-activated inhaler ptins fr bth maintenance treatment and rescue medicatin. AirDu RespiClick was apprved by the U.S. Fd and Drug Administratin (FDA) in January 2017 in three dses: 55/14 mcg, 113/14 mcg and 232/14 mcg administered as ne inhalatin twice daily. AirDu RespiClick cntains medicatin delivered via Teva s RespiClick breath-activated, multi-dse dry pwder inhaler (MDPI), which is used with ther apprved medicines in Teva s respiratry prduct prtfli. Abut AirDu RespiClick (Fluticasne Prpinate and Salmeterl) Inhalatin Pwder and authrized generic fluticasne prpinate and salmeterl inhalatin pwder (multidse dry pwder inhaler) The fllwing Indicatin and Imprtant Safety Infrmatin are applicable t bth AirDu RespiClick and its authrized generic.

2 AirDu RespiClick is indicated fr the treatment f asthma in patients aged 12 years and lder. AirDu RespiClick is nly fr patients uncntrlled n an ICS r whse disease severity clearly warrants an ICS/LABA. Imprtant Limitatin f Use: AirDu RespiClick is NOT indicated fr the relief f acute brnchspasm. IMPORTANT SAFETY INFORMATION WARNING: ASTHMA-RELATED DEATH Lng-acting beta 2 -adrenergic agnists (LABA), such as salmeterl, ne f the active ingredients in AirDu RespiClick, increase the risk f asthma-related death. Data frm a large placeb-cntrlled US trial that cmpared the safety f salmeterl with placeb added t usual asthma therapy shwed an increase in asthma-related deaths in subjects receiving salmeterl (13 deaths ut f 13,176 subjects treated fr 28 weeks n salmeterl versus 3 deaths ut f 13,179 subjects n placeb). Currently available data are inadequate t determine whether cncurrent use f inhaled crticsterids r ther lng-term asthma cntrl drugs mitigates the increased risk f asthma-related death frm LABA. Available data frm cntrlled clinical trials suggest that LABA increase the risk f asthma-related hspitalizatin in pediatric and adlescent patients Therefre, when treating patients with asthma, physicians shuld nly prescribe AirDu RespiClick fr patients nt adequately cntrlled n a lng-term asthma cntrl medicatin, such as an inhaled crticsterid, r whse disease severity clearly warrants initiatin f treatment with bth an inhaled crticsterid and a LABA. Once asthma cntrl is achieved and maintained, assess the patient at regular intervals and step dwn therapy (e.g., discntinue AirDu RespiClick) if pssible withut lss f asthma cntrl and maintain the patient n a lng-term asthma cntrl medicatin, such as an inhaled crticsterid. D nt use AirDu RespiClick fr patients whse asthma is adequately cntrlled n lw- r medium-dse inhaled crticsterids Cntraindicatins: AirDu RespiClick is cntraindicated in Primary treatment f status asthmaticus r ther acute episdes f asthma where intensive measures are required Patients with knwn severe hypersensitivity t milk prteins r knwn hypersensitivity t fluticasne prpinate r any f the excipients Deteriratin f Disease and Acute Episdes: Serius acute respiratry events, including fatalities, have been reprted when salmeterl, a cmpnent f AirDu RespiClick, has been initiated in patients with significantly wrsening r acutely deterirating asthma. AirDu RespiClick shuld nt be initiated in patients during rapidly deterirating r ptentially life-threatening episdes f asthma. AirDu RespiClick is nt indicated fr the relief f acute brnchspasm. An inhaled, shrt-acting beta 2 -agnist, nt AirDu RespiClick, shuld be used t relieve acute symptms such as shrtness f breath Excessive Use and Use with Other Lng acting Beta 2 -Agnists: AirDu RespiClick shuld nt be used mre ften than recmmended, at higher dses than recmmended, r in cnjunctin with ther

3 medicines cntaining LABA, as an verdse may result. Clinically significant cardivascular effects and fatalities have been reprted in assciatin with excessive use f inhaled sympathmimetic drugs. Patients using AirDu RespiClick shuld nt use anther medicine cntaining a LABA (e.g., salmeterl, frmterl fumarate, arfrmterl tartrate, indacaterl) fr any reasn Lcal Effects f Inhaled Crticsterids: Orpharyngeal candidiasis has ccurred in patients treated with AirDu RespiClick.Advise patients t rinse the muth with water withut swallwing fllwing inhalatin Immunsuppressin: Patients wh use crticsterids are at risk fr ptential wrsening f existing tuberculsis; fungal, bacterial, viral, r parasitic infectins; r cular herpes simplex. A mre serius r even fatal curse f chickenpx r measles may ccur in susceptible patients. Use with cautin, if at all, in patients with the abve because f the ptential fr wrsening f these infectins Transferring Patients frm Systemic Crticsterid Therapy: Particular care is needed fr patients wh have been transferred frm systemically active crticsterids t inhaled crticsterids because deaths due t adrenal insufficiency have ccurred in patients with asthma during and after transfer frm systemic crticsterids t less systemically available inhaled crticsterids. Taper patients slwly frm systemic crticsterids if transferring t AirDu RespiClick Hypercrticism and Adrenal Suppressin: Because f the pssibility f significant systemic absrptin f inhaled crticsterids, patients treated with AirDu RespiClick shuld be bserved carefully fr any evidence f systemic crticsterid effects. If such effects ccur, the dsage f AirDu RespiClick shuld be reduced slwly, cnsistent with accepted prcedures fr reducing systemic crticsterids, and fr management f asthma symptms Drug Interactins with Strng Cytchrme P450 3A4 Inhibitrs: The use f strng cytchrme P450 3A4 (CYP3A4) inhibitrs (e.g., ritnavir, atazanavir, clarithrmycin, indinavir, itracnazle, nefazdne, nelfinavir, saquinavir, ketcnazle, telithrmycin) with AirDu RespiClick is nt recmmended because increased systemic crticsterid and increased cardivascular adverse effects may ccur Paradxical Brnchspasm and Upper Airway Symptms: AirDu RespiClick can prduce paradxical brnchspasm, which may be life-threatening. If paradxical brnchspasm ccurs fllwing dsing with inhaled fluticasne prpinate/salmeterl medicines, it shuld be treated immediately with an inhaled, shrt-acting brnchdilatr; inhaled fluticasne prpinate/salmeterl medicines shuld be discntinued immediately; and alternative therapy shuld be instituted. Upper airway symptms f laryngeal spasm, irritatin, r swelling, such as stridr and chking, have been reprted Hypersensitivity Reactins, Including Anaphylaxis: Immediate hypersensitivity reactins (e.g., urticaria, angiedema, rash, brnchspasm, hyptensin), including anaphylaxis, may ccur after administratin f AirDu RespiClick. Discntinue AirDu RespiClick if such reactins ccur Cardivascular and Central Nervus System Effects: AirDu RespiClick shuld be used with cautin in patients with cardivascular disrders, especially crnary insufficiency, cardiac arrhythmias, and hypertensin. Salmeterl, a cmpnent f AirDu RespiClick, can prduce clinically significant cardivascular effects in sme patients as measured by pulse rate, bld pressure, and/r symptms. If such effects ccur, AirDu RespiClick may need t be discntinued Reductin in Bne Mineral Density (BMD): Decreases in BMD have been bserved with lng-term administratin f prducts cntaining inhaled crticsterids. Patients with majr risk factrs fr decreased bne mineral cntent, such as prlnged immbilizatin, family histry f steprsis, r

4 chrnic use f drugs that can reduce bne mass (e.g., anticnvulsants, ral crticsterids) shuld be mnitred and treated with established standards f care Effect n Grwth: Inhaled crticsterids, including AirDu RespiClick, may cause a reductin in grwth velcity when administered t pediatric patients. Mnitr the grwth f pediatric patients receiving AirDu RespiClick rutinely (e.g., via stadimetry). Titrate each patient s dsage t the lwest dsage that effectively cntrls his/her symptms Glaucma and Cataracts: Glaucma, increased intracular pressure, and cataracts have been reprted in patients with asthma fllwing the lng-term administratin f inhaled crticsterids, including fluticasne prpinate. Therefre, clse mnitring is warranted in patients with a change in visin r with a histry f increased intracular pressure, glaucma, and/r cataracts Esinphilic Cnditins and Churg-Strauss Syndrme: Systemic esinphilic cnditins, such as Churg-Strauss syndrme, may ccur. These events usually, but nt always, have been assciated with the reductin and/r withdrawal f ral crticsterid therapy fllwing the intrductin f fluticasne prpinate. Be alert t esinphilia, vasculitic rash, wrsening pulmnary symptms, cardiac cmplicatins, and/r neurpathy Cexisting Cnditins: Use with cautin in patients with cnvulsive disrders, thyrtxicsis, diabetes mellitus, ketacidsis, and in patients wh are unusually respnsive t sympathmimetic amines Hypkalemia and Hyperglycemia: Be alert t hypkalemia and hyperglycemia Adverse Reactins: Mst cmmn adverse reactins ( 3%) in patients taking AirDu RespiClick 55/14 mcg twice daily, 113/14 mcg twice daily, 232/14 mcg twice daily, and placeb, respectively, were naspharyngitis (8.6%, 4.8%, 6.9%, 4.4%), ral candidiasis (1.6%, 2.2%, 3.4%, 0.7%), back pain (3.1%, 0.7%, 0%, 1.8%), headache (5.5%, 4.8%, 2.8%, 4.4%), and cugh (2.3%, 3.7%, 0.7%, 2.6%) Drug Interactins: Inhibitrs f Cytchrme P450 3A4: The use f strng CYP3A4 inhibitrs (e.g., ritnavir, atazanavir, clarithrmycin, indinavir, itracnazle, nefazdne, nelfinavir, saquinavir, ketcnazle, telithrmycin) with AirDu RespiClick is nt recmmended because increased systemic crticsterid and increased cardivascular adverse effects may ccur Mnamine Oxidase Inhibitrs and Tricyclic Antidepressants: AirDu RespiClick shuld be administered with extreme cautin t patients being treated with mnamine xidase inhibitrs r tricyclic antidepressants, r within 2 weeks f discntinuatin f such agents, because the actin f salmeterl, a cmpnent f AirDu RespiClick, n the vascular system may be ptentiated by these agents Beta-Adrenergic Receptr Blcking Agents: Beta-blckers nt nly blck the pulmnary effect f beta-agnists, such as salmeterl, a cmpnent f AirDu RespiClick, but may als prduce severe brnchspasm in patients with asthma. Therefre, patients with asthma shuld nt nrmally be treated with beta-blckers Nn-Ptassium-Sparing Diuretics: The ECG changes and/r hypkalemia that may result frm the administratin f nn ptassium-sparing diuretics (such as lp r thiazide diuretics) can be acutely wrsened by beta-agnists, such as salmeterl, a cmpnent f AirDu RespiClick. Cautin is advised in the cadministratin f AirDu RespiClick with nn ptassium-sparing diuretics Use in Specific Ppulatins: Since bth fluticasne prpinate and salmeterl are predminantly cleared by hepatic metablism, impairment f liver functin may lead t accumulatin f fluticasne

5 prpinate and salmeterl in plasma. Therefre, patients with hepatic disease shuld be clsely mnitred Please click here fr full Prescribing Infrmatin, including Bxed WARNING: natesalmeterlinhalatinpwder_pi.pdf Abut Asthma Asthma is a chrnic (lng term) disease usually characterized by airway inflammatin and narrwing f the airways, which can vary ver time. Asthma may cause recurring perids f wheezing (a whistling sund when yu breathe), chest tightness, shrtness f breath and cughing that ften ccurs at night r early in the mrning. Withut apprpriate treatment, asthma symptms may becme mre severe and result in an asthma attack, which can lead t hspitalizatin and even death. Abut Teva Respiratry Teva Respiratry develps and delivers high-quality treatment ptins fr respiratry cnditins, including asthma, COPD and allergic rhinitis. The Teva Respiratry prtfli is centered n ptimizing respiratry treatment fr patients and healthcare prviders thrugh the develpment f nvel delivery systems and therapies that help address unmet needs. The cmpany s respiratry pipeline and clinical trial prgram are based n drug mlecules delivered in prprietary dry pwder frmulatins and breath-activated device technlgies, as well as a targeted bilgic treatment fr severe asthma. Thrugh research and clinical develpment, Teva Respiratry cntinually wrks t expand, strengthen and build upn its treatment prtfli t psitively impact the lives f the millins f patients living with respiratry disease. Abut Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading glbal pharmaceutical cmpany that delivers high-quality, patient-centric healthcare slutins used by apprximately 200 millin patients in 100 markets every day. Headquartered in Israel, Teva is the wrld s largest generic medicines prducer, leveraging its prtfli f mre than 1,800 mlecules t prduce a wide range f generic prducts in nearly every therapeutic area. In specialty medicines, Teva has the wrld-leading innvative treatment fr multiple sclersis as well as late-stage develpment prgrams fr ther disrders f the central nervus system, including mvement disrders, migraine, pain and neurdegenerative cnditins, as well as a brad prtfli f respiratry prducts. Teva is leveraging its generics and specialty capabilities in rder t seek new ways f addressing unmet patient needs by cmbining drug develpment with devices, services and technlgies. Teva's net revenues in 2016 were $21.9 billin. Fr mre infrmatin, visit Cautinary Nte Regarding Frward-Lking Statements This press release cntains frward-lking statements within the meaning f the Private Securities Litigatin Refrm Act f 1995 regarding the launch f AirDu RespiClick and its Authrized Generic,

6 which are based n management s current beliefs and expectatins and are subject t substantial risks and uncertainties, bth knwn and unknwn, that culd cause ur future results, perfrmance r achievements t differ significantly frm that expressed r implied by such frward-lking statements. Imprtant factrs that culd cause r cntribute t such differences include risks relating t: the uncertainty f the cmmercial success f AirDu RespiClick and its Authrized Generic; ur generics medicines business, including: that we are substantially mre dependent n this business, with its significant attendant risks, fllwing ur acquisitin f Allergan plc s wrldwide generic pharmaceuticals business ( Actavis Generics ); ur ability t realize the anticipated benefits f the acquisitin (and any delay in realizing thse benefits) r difficulties in integrating Actavis Generics; the increase in the number f cmpetitrs targeting generic pprtunities and seeking U.S. market exclusivity fr generic versins f significant prducts; price ersin relating t ur generic prducts, bth frm cmpeting prducts and as a result f increased gvernmental pricing pressures; and ur ability t take advantage f high-value bisimilar pprtunities; ur specialty medicines business, including: cmpetitin fr ur specialty prducts, especially Cpaxne, ur leading medicine, which faces cmpetitin frm existing and ptential additinal generic versins and rally-administered alternatives; ur ability t achieve expected results frm investments in ur prduct pipeline; cmpetitin frm cmpanies with greater resurces and capabilities; and the effectiveness f ur patents and ther measures t prtect ur intellectual prperty rights; ur business and peratins in general, including: ur ability t develp and cmmercialize additinal pharmaceutical prducts; manufacturing r quality cntrl prblems, which may damage ur reputatin fr quality prductin and require cstly remediatin; interruptins in ur supply chain; disruptins f ur r third party infrmatin technlgy systems r breaches f ur data security; the restructuring f ur manufacturing netwrk, including ptential related labr unrest; the impact f cntinuing cnslidatin f ur distributrs and custmers; and variatins in patent laws that may adversely affect ur ability t manufacture ur prducts; cmpliance, regulatry and litigatin matters, including: csts and delays resulting frm the extensive gvernmental regulatin t which we are subject; the effects f refrms in healthcare regulatin and reductins in pharmaceutical pricing, reimbursement and cverage; ptential additinal adverse cnsequences fllwing ur reslutin with the U.S. gvernment f ur FCPA investigatin; gvernmental investigatins int sales and marketing practices; ptential liability fr sales f generic prducts prir t a final reslutin f utstanding patent litigatin; prduct liability claims; increased gvernment scrutiny f ur patent settlement agreements; failure t cmply with cmplex Medicare and Medicaid reprting and payment bligatins; and envirnmental risks and ther factrs discussed in ur Annual Reprt n Frm 20-F fr the year ended December 31, 2016 ( Annual Reprt ), including in the sectin captined Risk Factrs, and in ur ther filings with the U.S. Securities and Exchange Cmmissin, which are available at and Frward-lking statements speak nly as f the date n which they are made, and we assume n bligatin t update r revise any frward-lking statements r ther infrmatin cntained herein, whether as a result f new infrmatin, future events r therwise. Yu are cautined nt t put undue reliance n these frward-lking statements. # # #

Annex III. Amendments to relevant sections of the Product Information

Annex III. Amendments to relevant sections of the Product Information Changes t the Prduct infrmatin as apprved by the CHMP n 13 Octber 2016, pending endrsement by the Eurpean Cmmissin Annex III Amendments t relevant sectins f the Prduct Infrmatin Nte: These amendments t

More information

Original Policy Date 12:2013

Original Policy Date 12:2013 MP 5.01.18 Xlair (Omalizumab) Medical Plicy Sectin Prescriptin Drugs Issu12:2013e 4:2006 Original Plicy Date 12:2013 Last Review Status/Date Lcal plicy/12:2013 Return t Medical Plicy Index Disclaimer Our

More information

WARNING: FATAL AND SERIOUS TOXICITIES: SEVERE DIARRHEA AND CARDIAC TOXICITIES

WARNING: FATAL AND SERIOUS TOXICITIES: SEVERE DIARRHEA AND CARDIAC TOXICITIES INDICATION FARYDAK (panbinstat) capsules, a histne deacetylase inhibitr, in cmbinatin with brtezmib and dexamethasne, is indicated fr the treatment f patients with multiple myelma wh have received at least

More information

MEDICATION GUIDE LEMTRADA (lem-tra-da) (alemtuzumab) Injection for intravenous infusion

MEDICATION GUIDE LEMTRADA (lem-tra-da) (alemtuzumab) Injection for intravenous infusion MEDICATION GUIDE LEMTRADA (lem-tra-da) (alemtuzumab) Injectin fr intravenus infusin Read this Medicatin Guide befre yu start receiving LEMTRADA and befre yu begin each treatment curse. There may be new

More information

SUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES. ANTI-OBESITY AGENTS Generic Brand HICL GCN Exception/Other QSYMIA 32515, 32744, 32746, 32745

SUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES. ANTI-OBESITY AGENTS Generic Brand HICL GCN Exception/Other QSYMIA 32515, 32744, 32746, 32745 Generic Brand HICL GCN Exceptin/Other NALTREXONE CONTRAVE ER 41389 /BUPROPION LORCASERIN BELVIQ 34733 PHENTERMINE PHENTERMINE 20691 20692 20693 20713 PHENTERMINE LOMAIRA 20715 PHENTERMINE/TO PIRAMATE GUIDELINES

More information

Vaccine Information Statement: LIVE INTRANASAL INFLUENZA VACCINE

Vaccine Information Statement: LIVE INTRANASAL INFLUENZA VACCINE Vaccine Infrmatin Statement: LIVE INTRANASAL INFLUENZA VACCINE Many Vaccine Infrmatin Statements are available in Spanish and ther languages. See www.immunize.rg/vis. Hjas de Infrmacián Sbre Vacunas están

More information

Completing the NPA online Patient Safety Incident Report form: 2016

Completing the NPA online Patient Safety Incident Report form: 2016 Cmpleting the NPA nline Patient Safety Incident Reprt frm: 2016 The infrmatin cntained within this dcument is in line with the current Data Prtectin Act (DPA) requirements. This infrmatin may be subject

More information

Family Medicine Clinical Pharmacy Forum Vol. 3, Issue 5 (September/October 2007)

Family Medicine Clinical Pharmacy Forum Vol. 3, Issue 5 (September/October 2007) 1 Family Medicine Clinical Pharmacy Frum Vl. 3, Issue 5 (September/Octber 2007) Family Medicine Clinical Pharmacy Frum is a brief bi-mnthly publicatin frm the Family Medicine clinical pharmacists distributed

More information

Osteoporosis Fast Facts

Osteoporosis Fast Facts Osteprsis Fast Facts Fast Facts n Osteprsis Definitin Osteprsis, r prus bne, is a disease characterized by lw bne mass and structural deteriratin f bne tissue, leading t bne fragility and an increased

More information

Solid Organ Transplant Benefits to Change for Texas Medicaid

Solid Organ Transplant Benefits to Change for Texas Medicaid Slid Organ Transplant Benefits t Change fr Texas Medicaid Infrmatin psted February 13, 2015 Nte: All new and updated prcedure cdes and their assciated reimbursement rates are prpsed benefits pending a

More information

MEDICATION GUIDE. (fingolimod) capsules

MEDICATION GUIDE. (fingolimod) capsules MEDICATION GUIDE GILENYA (je-len-yah) (finglimd) capsules Read this Medicatin Guide befre yu start using GILENYA and each time yu get a refill. There may be new infrmatin. This infrmatin des nt take the

More information

NUCYNTA ER (tapentadol extended-release tablets) Fact Sheet

NUCYNTA ER (tapentadol extended-release tablets) Fact Sheet NUCYNTA ER (tapentadl extended-release tablets) Fact Sheet What is NUCYNTA ER (prnunced 'new-sinn-tah')? NUCYNTA ER (tapentadl extended-release tablets), an ral analgesic taken twice daily, is nw apprved

More information

A fake medicine that passes itself off as a real, authorised medicine. (1)

A fake medicine that passes itself off as a real, authorised medicine. (1) Falsified medicines Index 1 Intrductin 2 Types f falsified medicines 3 Eurpean regulatin n falsified medicines 4 Risks f falsified medicines 5 Buying medicine nline safely 6 References 7 Further resurces

More information

MEDICATION GUIDE Pioglitazone (pie-oh-glit-ah-zohn) and Metformin (met-fore-min) Hydrochloride Tablets USP

MEDICATION GUIDE Pioglitazone (pie-oh-glit-ah-zohn) and Metformin (met-fore-min) Hydrochloride Tablets USP MEDICATION GUIDE Piglitazne (pie-h-glit-ah-zhn) and Metfrmin (met-fore-min) Hydrchlride Tablets USP Read this Medicatin Guide carefully befre yu start taking piglitazne and metfrmin hydrchlride tablets

More information

2017 Optum, Inc. All rights reserved BH1124_112017

2017 Optum, Inc. All rights reserved BH1124_112017 1) What are the benefits t clients f encuraging the use f MAT? Withut MAT, 90% f individuals with Opiid Use Disrder (OUD) will relapse within ne year. With MAT, the relapse rate fr thse with OUD decreases

More information

EXECUTIVE SUMMARY INNOVATION IS THE KEY TO CHANGING THE PARADIGM FOR THE TREATMENT OF PAIN AND ADDICTION TO CREATE AN AMERICA FREE OF OPIOID ADDICTION

EXECUTIVE SUMMARY INNOVATION IS THE KEY TO CHANGING THE PARADIGM FOR THE TREATMENT OF PAIN AND ADDICTION TO CREATE AN AMERICA FREE OF OPIOID ADDICTION EXECUTIVE SUMMARY INNOVATION IS THE KEY TO CHANGING THE PARADIGM FOR THE TREATMENT OF PAIN AND ADDICTION TO CREATE AN AMERICA FREE OF OPIOID ADDICTION The Bitechnlgy Innvatin Organizatin (BIO) and ur member

More information

CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION

CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION INSTRUCTIONS This is an infrmed cnsent dcument which has been prepared t help yur Dctr infrm yu cncerning fat reductin with an injectable medicatin, its risks,

More information

You may have a higher risk of bleeding if you take warfarin sodium tablets and:

You may have a higher risk of bleeding if you take warfarin sodium tablets and: MEDICATION GUIDE Warfarin (WAR-far-in) Sdium (SO-dee-um) Tablets USP The 7.5 mg tablets cntain FD&C Yellw N. 5 (tartrazine), which may cause allergic-type reactins (including brnchial asthma) in certain

More information

Vaccine Information Statement: PNEUMOCOCCAL CONJUGATE VACCINE

Vaccine Information Statement: PNEUMOCOCCAL CONJUGATE VACCINE Vaccine Infrmatin Statement: PNEUMOCOCCAL CONJUGATE VACCINE Many Vaccine Infrmatin Statements are available in Spanish and ther languages. See www.immunize.rg/vis. Hjas de Infrmacián Sbre Vacunas están

More information

MEDICATION GUIDE Pioglitazone and Metformin Hydrochloride (PYE o GLI ta zone and met FOR min HYE-droe- KLOR-ide)Tablets, USP

MEDICATION GUIDE Pioglitazone and Metformin Hydrochloride (PYE o GLI ta zone and met FOR min HYE-droe- KLOR-ide)Tablets, USP MEDICATION GUIDE Piglitazne and Metfrmin Hydrchlride (PYE GLI ta zne and met FOR min HYE-dre- KLOR-ide)Tablets, USP Read this Medicatin Guide carefully befre yu start taking piglitazne and metfrmin hydrchlride

More information

Important Information

Important Information Grup Health Pharmacy Administratin GSE-B2N-02 2921 Naches Ave SW PO Bx 9009 Rentn, WA 98057-9009 Grup Health Cperative Grup Health Optins, Inc. ghc.rg Imprtant Infrmatin February 6, 2017 Dear Prvider,

More information

CDC Influenza Division Key Points MMWR Updates February 20, 2014

CDC Influenza Division Key Points MMWR Updates February 20, 2014 CDC Influenza Divisin Key Pints MMWR Updates In this dcument: Summary Key Messages Seasnal Influenza Vaccine Effectiveness: Interim Adjusted Estimates Influenza Surveillance Update: September 29, 2013-February

More information

CONSENT FORM - TESTOSTERONE FOR TRANSGENDER CLIENTS

CONSENT FORM - TESTOSTERONE FOR TRANSGENDER CLIENTS CONSENT FORM - TESTOSTERONE FOR TRANSGENDER CLIENTS Yu want t take teststerne t masculinize yur bdy. Befre taking it, there are several things yu need t knw abut. They are the pssible advantages, disadvantages,

More information

US Public Health Service Clinical Practice Guidelines for PrEP

US Public Health Service Clinical Practice Guidelines for PrEP Webcast 1.3 US Public Health Service Clinical Practice Guidelines fr PrEP P R E S ENTED BY: M A R K T H R U N, M D A S S O C I AT E P R O F E S S O R, U N I V E R S I T Y O F C O L O R A D O, D I V I S

More information

Influenza (Flu) Fact Sheet

Influenza (Flu) Fact Sheet Influenza (Flu) Fact Sheet What is the flu? The flu is a cntagius respiratry illness caused by influenza viruses. It can cause mild t severe illness, and at times can lead t death. Sme peple, such as lder

More information

Asthma inhalers, medicines and treatments

Asthma inhalers, medicines and treatments Asthma inhalers, medicines and treatments Reliever inhalers Yur Emergency Rescue Reliever Everyne with asthma shuld ALWAYS carry a reliever (blue inhaler) inhaler at all the time s it s n hand in an emergency

More information

PATIENT INFORMATION. Rosuvastatin calcium tablets are used along with diet to:

PATIENT INFORMATION. Rosuvastatin calcium tablets are used along with diet to: PATIENT INFORMATION Rsuvastatin Calcium (re-soo-va-stat-in KAL-see-um) Tablets Read this Patient Infrmatin carefully befre yu start taking rsuvastatin calcium tablets and each time yu get a refill. If

More information

RoActemra (tocilizumab) for Giant Cell Arteritis (GCA) subcutaneous (SC) formulation

RoActemra (tocilizumab) for Giant Cell Arteritis (GCA) subcutaneous (SC) formulation RActemra (tcilizumab) fr Giant Cell Arteritis (GCA) subcutaneus (SC) frmulatin What yu shuld knw abut RActemra This brchure prvides key infrmatin t assist in the patient s understanding f the benefits

More information

Tick fever is a cattle disease caused by any one of the following blood parasites:

Tick fever is a cattle disease caused by any one of the following blood parasites: Tick fever Tick fever is a cattle disease caused by any ne f the fllwing bld parasites: Babesia bvis Babesia bigemina Anaplasma marginale These parasites are all transmitted by the cattle tick (Bphilus

More information

MEDICATION GUIDE. (canagliflozin) Tablets

MEDICATION GUIDE. (canagliflozin) Tablets MEDICATION GUIDE INVOKANA (in-v-kahn-uh) (canagliflzin) Tablets What is the mst imprtant infrmatin I shuld knw abut INVOKANA? INVOKANA can cause imprtant side effects, including: Dehydratin. INVOKANA can

More information

Tendon problems can happen in people of all ages who take levofloxacin. Tendons are tough cords of tissue that connect muscles to bones.

Tendon problems can happen in people of all ages who take levofloxacin. Tendons are tough cords of tissue that connect muscles to bones. Medicatin Guide LEVOFLOXACIN (LEE ve FLOX a sin) INJECTION, 25 mg/ml and LEVOFLOXACIN (LEE ve FLOX a sin) INJECTION in 5% Dextrse fr Intravenus Use Read this Medicatin Guide befre yu start taking levflxacin

More information

Triumeq (abacavir, dolutegravir and lamivudine) Product Backgrounder for US Media

Triumeq (abacavir, dolutegravir and lamivudine) Product Backgrounder for US Media Triumeq (abacavir, dlutegravir and lamivudine) Prduct Backgrunder fr US Media What is Triumeq and wh is Triumeq fr? Triumeq (abacavir 600mg, dlutegravir 50mg and lamivudine 300mg) is the first dlutegravir-based

More information

Diabetes Canada Pre-Budget Consultation Submission. Standing Committee on Finance and Economic Affairs. Government of Ontario.

Diabetes Canada Pre-Budget Consultation Submission. Standing Committee on Finance and Economic Affairs. Government of Ontario. Diabetes Canada 2018 Pre-Budget Cnsultatin Submissin Standing Cmmittee n Finance and Ecnmic Affairs Gvernment f Ontari January 17, 2018 1 Executive Summary Tday, abut 4.4 millin Ontarians, r 29 per cent

More information

If you have any doubts or queries about your medication, please contact your doctor or pharmacist.

If you have any doubts or queries about your medication, please contact your doctor or pharmacist. Bayer plc Bayer Huse Strawberry Hill Newbury Berkshire RG14 1JA United Kingdm Telephne: +44 (0)1635 563 000 Facsimile: +44 (0)1635 563 393 Cmpany Web Site: http://www.bayer.c.uk Due t regulatry changes,

More information

Frequently Asked Questions: IS RT-Q-PCR Testing

Frequently Asked Questions: IS RT-Q-PCR Testing Questins 1. What is chrnic myelid leukemia (CML)? 2. Hw des smene knw if they have CML? 3. Hw is smene diagnsed with CML? Frequently Asked Questins: IS RT-Q-PCR Testing Answers CML is a cancer f the bld

More information

SHARED CARE AGREEMENT. November Dronedarone (Multaq ) For the treatment and management of non permanent atrial fibrillation

SHARED CARE AGREEMENT. November Dronedarone (Multaq ) For the treatment and management of non permanent atrial fibrillation SHARED CARE AGREEMENT Oxfrdshire Nvember 2011 Drnedarne (Multaq ) Fr the treatment and management f nn permanent atrial fibrillatin INTRODUCTION There shuld be willing cnsent f all parties t enter int

More information

Glaucoma Interviews: Due Tuesday, May 22 nd

Glaucoma Interviews: Due Tuesday, May 22 nd Glaucma Interviews: Due Tuesday, May 22 nd 1) Read the glaucma article well! It will explain what it is, plus tell yu sme symptms and risk factrs. Yu may want t use a highlighter r pen t mark imprtant

More information

Safety of HPV vaccination: A FIGO STATEMENT

Safety of HPV vaccination: A FIGO STATEMENT FIGO Statement n HPV Vaccinatin Safety, August 2nd, 2013 Safety f HPV vaccinatin: A FIGO STATEMENT July, 2013 Human papillmavirus vaccines are used in many cuntries; glbally, mre than 175 millin dses have

More information

Related Policies None

Related Policies None Medical Plicy MP 3.01.501 Guidelines fr Cverage f Mental and Behaviral Health Services Last Review: 8/30/2017 Effective Date: 8/30/2017 Sectin: Mental Health End Date: 08/19/2018 Related Plicies Nne DISCLAIMER

More information

MEDICATION GUIDE QSYMIA (Kyoo sim ee uh) (phentermine and topiramate extended-release) Capsules CIV

MEDICATION GUIDE QSYMIA (Kyoo sim ee uh) (phentermine and topiramate extended-release) Capsules CIV MEDICATION GUIDE QSYMIA (Ky sim ee uh) (phentermine and tpiramate extended-release) Capsules CIV Read this Medicatin Guide befre yu start taking Qsymia and each time yu get a refill. There may be new infrmatin.

More information

My Symptoms and Medical History for Adult Chronic Immune Thrombocytopenia (ITP)

My Symptoms and Medical History for Adult Chronic Immune Thrombocytopenia (ITP) My Symptms and Medical Histry fr Adult Chrnic Immune Thrmbcytpenia (ITP) Call t talk t a registered nurse 1-855-7Nplate (1-855-767-5283), Mnday Friday, 9:00 AM 9:00 PM ET Indicatin Nplate is a man-made

More information

Pennsylvania Guidelines on the Use of Opioids to Treat Chronic Noncancer Pain

Pennsylvania Guidelines on the Use of Opioids to Treat Chronic Noncancer Pain Pennsylvania Guidelines n the Use f Opiids t Treat Chrnic Nncancer Pain Chrnic pain is a majr health prblem in the United States, ccurring with a pintprevalence f abut ne-third f the US ppulatin.(1) Mre

More information

Press Release. Adocia: Activity and results for the first half of 2013

Press Release. Adocia: Activity and results for the first half of 2013 Press Release Adcia: Activity and results fr the first half f 2013 Intensificatin f R&D activity ahead f the launch f three clinical trials fr insulin prjects, starting in the secnd half f 2013 Net result

More information

BRCA1 and BRCA2 Mutations

BRCA1 and BRCA2 Mutations BRCA1 and BRCA2 Mutatins ROBERT LEVITT, MD JESSICA BERGER-WEISS, MD ADRIENNE POTTS, MD HARTAJ POWELL, MD, MPH COURTNEY LEVENSON, MD LAUREN BURNS, MSN, RN, WHNP OBGYNCWC.COM v Cancer is a cmplex disease

More information

PART III: CONSUMER INFORMATION

PART III: CONSUMER INFORMATION IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION Pr ZERIT Stavudine This leaflet is Part III f a three-part Prduct Mngaph published when ZERIT was apprved fr sale in Canada and is designed specifically

More information

MEDICATION GUIDE. (Interferon alfa-2b)

MEDICATION GUIDE. (Interferon alfa-2b) MEDICATION GUIDE INTRON A (In-trn-aye) (Interfern alfa-2b) Read this Medicatin Guide befre yu start taking INTRON A, and each time yu get a refill. There may be new infrmatin. This infrmatin des nt take

More information

MEDICATION GUIDE REVLIMID (rev-li-mid) (lenalidomide) capsules What is the most important information I should know about REVLIMID?

MEDICATION GUIDE REVLIMID (rev-li-mid) (lenalidomide) capsules What is the most important information I should know about REVLIMID? MEDICATION GUIDE REVLIMID (rev-li-mid) (lenalidmide) capsules What is the mst imprtant infrmatin I shuld knw abut REVLIMID? Befre yu begin taking REVLIMID, yu must read and agree t all f the instructins

More information

PATIENT INFORMATION. effective for the treatment of the flu in people with long-time (chronic) heart problems or breathing problems.

PATIENT INFORMATION. effective for the treatment of the flu in people with long-time (chronic) heart problems or breathing problems. PATIENT INFORMATION capsules, fr ral use fr ral suspensin What is TAMIFLU? TAMIFLU is a prescriptin medicine used t: treat the flu (influenza) in peple 2 weeks f age and lder wh have had flu symptms fr

More information

FDA Dietary Supplement cgmp

FDA Dietary Supplement cgmp FDA Dietary Supplement cgmp FEBRUARY 2009 OVERVIEW Summary The Fd and Drug Administratin (FDA) has issued a final rule regarding current gd manufacturing practices (cgmp) fr dietary supplements that establishes

More information

LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST

LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST OPTUM LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY / APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED

More information

Cancer Association of South Africa (CANSA)

Cancer Association of South Africa (CANSA) Cancer Assciatin f Suth Africa (CANSA) Fact Sheet and Psitin Statement n Cannabis in Suth Africa Intrductin Cannabis is a drug that cmes frm Indian hemp plants such as Cannabis sativa and Cannabis indica.

More information

Breast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)

Breast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018) Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synpsis fr Public Disclsure This clinical study synpsis is prvided in line with Behringer Ingelheim s Plicy n Transparency and Publicatin f Clinical Study Data. The synpsis which is

More information

Generic Immunosuppressants in the Specialist Area of Transplantation Consensus on Implications and Practical Recommendations

Generic Immunosuppressants in the Specialist Area of Transplantation Consensus on Implications and Practical Recommendations Dear Clleague Generic Immunsuppressants in the Specialist Area f Transplantatin Cnsensus n Implicatins and Practical Recmmendatins Executive Summary Slid-rgan transplants are the best pssible treatment

More information

What is Asthma? A collaborative effort of Children s Hospital of Pittsburgh of UPMC and The Pennsylvania Child Welfare Resource Center

What is Asthma? A collaborative effort of Children s Hospital of Pittsburgh of UPMC and The Pennsylvania Child Welfare Resource Center A cllabrative effrt f Children s Hspital f Pittsburgh f UPMC and The Pennsylvania Child Welfare Resurce Center What is Asthma? Jennifer E. Wlfrd, DO, MPH, FAAP Children s Hspital f Pittsburgh, Divisin

More information

Head and neck cancers are often treated with radiotherapy. Radiotherapy can lead to faster rates of tooth decay and poor healing in the mouth.

Head and neck cancers are often treated with radiotherapy. Radiotherapy can lead to faster rates of tooth decay and poor healing in the mouth. DENTAL EXTRACTION This infrmatin aims t help yu understand the peratin, what is invlved and sme cmmn cmplicatins that may ccur. It may help answer sme f yur questins and help yu think f ther questins that

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER (Sanfi-Aventis France), NT001 Suppliers submissin f the SRA apprved text Octber 2016 Name f the medicinal prduct Text bx PACKAGE LEAFLET: INFORMATION FOR THE USER NOTEZINE 100 mg, scred tablets Diethylcarbamazine

More information

Flu Season Key Points ( )

Flu Season Key Points ( ) 2014-2015 Flu Seasn Key Pints (10-31-14) Cntents Overarching Framewrk f CDC Influenza Messaging... 3 Take 3 Messages... 3 Statements fr General Audiences... 4 Disease... 4 Vaccinatin... 6 Vaccinatin Timing...

More information

MEDICATION GUIDE. Reference ID:

MEDICATION GUIDE. Reference ID: MEDICATION GUIDE GLYXAMBI (glik-sam-bee) (empagliflzin and linagliptin) Tablets Read this Medicatin Guide carefully befre yu start taking GLYXAMBI and each time yu get a refill. There may be new infrmatin.

More information

CDC Influenza Technical Key Points February 15, 2018

CDC Influenza Technical Key Points February 15, 2018 CDC Influenza Technical Key Pints In this dcument: Summary Key Pints U.S. Vaccine Effectiveness U.S. Flu Activity Update Summary Key Pints On Thursday, tw influenza-related reprts appeared in the Mrbidity

More information

Benepali (etanercept): Brief training on additional Risk Minimisation Measures

Benepali (etanercept): Brief training on additional Risk Minimisation Measures Benepali (etanercept): Brief training n additinal Risk Minimisatin Measures Slide Deck fr Healthcare Prfessinal (HCP) Training Versin 9.0; 22 January 2016 UK/IE 1 Benepali (etanercept) This medicine is

More information

Medication Guide MORPHINE SULFATE (mor-pheen) Oral Solution (CII)

Medication Guide MORPHINE SULFATE (mor-pheen) Oral Solution (CII) Medicatin Guide MORPHINE SULFATE (mr-pheen) Oral Slutin (CII) IMPORTANT: Keep Mrphine Sulfate Oral Slutin in a safe place away frm children. Accidental use by a child is a medical emergency and can cause

More information

/0515 Medication Guide Aripiprazole Tablets

/0515 Medication Guide Aripiprazole Tablets 8415721/0515 Medicatin Guide Aripiprazle Tablets (air-eh-pip-rah-zle) Read this Medicatin Guide befre yu start taking aripiprazle tablets and each time yu get a refill. There may be new infrmatin. This

More information

1.11 INSULIN INFUSION PUMP MANAGEMENT INPATIENT

1.11 INSULIN INFUSION PUMP MANAGEMENT INPATIENT WOMEN AND NEWBORN HEALTH SERVICE CLINICAL GUIDELINES SECTION A: GUIDELINES RELEVANT TO OBSTETRICS AND GYNAECOLOGY 1 STANDARD PROTOCOLS 1.11 INSULIN INFUSION PUMP MANAGEMENT - INPATIENT Authrised by: OGCCU

More information

Swindon Joint Strategic Needs Assessment Bulletin

Swindon Joint Strategic Needs Assessment Bulletin Swindn Jint Strategic Needs Assessment Bulletin Swindn Diabetes 2017 Key Pints: This JSNA gives health facts abut peple with diabetes r peple wh might get diabetes in Swindn. This helps us t plan fr medical

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial infrmatin prvided in this public disclsure synpsis is supplied fr infrmatinal purpses nly. Please nte that the results reprted in any single trial may nt reflect the verall ptential

More information

Methadone Maintenance Treatment for Opioid Dependence

Methadone Maintenance Treatment for Opioid Dependence POLICY STATEMENT Methadne Maintenance Treatment fr Opiid Dependence APPROVED BY COUNCIL: May 2010 PUBLICATION DATE: Dialgue, Issue 2, 2010 Disclaimer: As f May 19, 2018 physicians n lnger require an exemptin

More information

Public consultation on the NHMRC s draft revised Australian alcohol guidelines for low-risk drinking

Public consultation on the NHMRC s draft revised Australian alcohol guidelines for low-risk drinking Public cnsultatin n the NHMRC s draft revised Australian alchl guidelines fr lw-risk drinking Recmmendatins frm The Cancer Cuncil Australia The Cancer Cuncil Australia is Australia s peak nn-gvernment

More information

Use of sacubitril valsartan for the treatment of symptomatic chronic heart failure with reduced ejection fraction. Shared Care Protocol

Use of sacubitril valsartan for the treatment of symptomatic chronic heart failure with reduced ejection fraction. Shared Care Protocol Oxfrdshire Clinical Cmmissining Grup Use f sacubitril valsartan fr the treatment f symptmatic chrnic heart failure with reduced ejectin fractin. Shared Care Prtcl This prtcl prvides prescribing and mnitring

More information

Press Release. Registered in Jersey, No , 22 Grenville Street, St Helier, Jersey JE4 8PX

Press Release.   Registered in Jersey, No , 22 Grenville Street, St Helier, Jersey JE4 8PX Press Release www.shire.cm Psitive Tp-line Results Shwn fr Vyvanse (lisdexamfetamine dimesylate) Capsules (CII) in Adults with Binge Eating Disrder Shire Plans t Submit a Supplemental New Drug Applicatin

More information

SUMMARY THE EUROPEAN COMMUNITY STRATEGY

SUMMARY THE EUROPEAN COMMUNITY STRATEGY SUMMARY THE EUROPEAN COMMUNITY STRATEGY FOR THE PHASEOUT OF CFCS IN MDIS 1. The Eurpean Cmmunity s transitin strategy fr the phaseut f CFCs in metered-dse inhalers (MDIs) was submitted t the Parties t

More information

Press Release. Adocia Reports Operational and Financial Results for the First Half of 2014

Press Release. Adocia Reports Operational and Financial Results for the First Half of 2014 Press Release Adcia Reprts Operatinal and Financial Results fr the First Half f 2014 Majr clinical results reprted n tw frmulatins based n insulin Sund financial psitin with apprximately EUR 16 millin

More information

A Phase I Study of CEP-701 in Patients with Refractory Neuroblastoma NANT (01-03) A New Approaches to Neuroblastoma Therapy (NANT) treatment protocol.

A Phase I Study of CEP-701 in Patients with Refractory Neuroblastoma NANT (01-03) A New Approaches to Neuroblastoma Therapy (NANT) treatment protocol. SAMPLE INFORMED CONSENT A Phase I Study f CEP-701 in Patients with Refractry Neurblastma NANT (01-03) A New Appraches t Neurblastma Therapy (NANT) treatment prtcl. The wrd yu used thrughut this dcument

More information

MEDICATION GUIDE Levofloxacin (lee-voe-flox-a-sin) Tablets, USP 250 mg Tablets, 500 mg Tablets, and 750 mg Tablets

MEDICATION GUIDE Levofloxacin (lee-voe-flox-a-sin) Tablets, USP 250 mg Tablets, 500 mg Tablets, and 750 mg Tablets MEDICATION GUIDE Levflxacin (lee-ve-flox-a-sin) Tablets, USP 250 mg Tablets, 500 mg Tablets, and 750 mg Tablets Read this Medicatin Guide befre yu start taking levflxacin tablets and each time yu get a

More information

Ischemic heart disease (angina/chest pain)

Ischemic heart disease (angina/chest pain) Ischemic heart disease (angina/chest pain) External resurces Stable angina: management NICE guidelines [CG126] Updated :Aug 2016 https://www.nice.rg.uk/guidance/cg126 Chest pain f recent nset [CG95] Nvember

More information

Significance of Chronic Kidney Disease in 2015

Significance of Chronic Kidney Disease in 2015 1 Significance f Chrnic Kidney Disease in 2015 There is still a requirement within QOF t keep a register f peple with CKD stages 3-5. The ther CKD QOF targets have been retired. This is because CKD care

More information

High Performance Network Quality Criteria for Designation

High Performance Network Quality Criteria for Designation Selected quality measures include: Specialty Measure Descriptin Allergy / Immunlgy Asthma Drug Mgt Vaccine Pneumnia Vaccine High Perfrmance Netwrk Quality Criteria fr Designatin AvMed has selected certain

More information

Commissioning Policy: South Warwickshire CCG (SWCCG)

Commissioning Policy: South Warwickshire CCG (SWCCG) Cmmissining Plicy: Suth Warwickshire CCG (SWCCG) Treatment Indicatin Criteria FreeStyle Libre Flash Cntinuus Glucse Mnitring System Type I Diabetes Prir apprval must be requested frm the Individual Funding

More information

Social Learning Theories

Social Learning Theories Scial Learning Theries - Careful scientific prcedures and methdlgy that characterize the behaviurist apprach Albert Bandura - Brn in small twn Alberta - Plish decent - Only sn with 5 sisters - Interested

More information

BP Thresholds for Medical Review

BP Thresholds for Medical Review BP Threshlds fr Medical Review Wmen presents t GP pstnatally with high bld pressure r referred t GP by midwife GP t review patient n the same day if BP>150/100. If BP (dne by midwife) persistently 140-149/90-99,

More information

CDC Influenza Division Key Points November 7, 2014

CDC Influenza Division Key Points November 7, 2014 In this dcument: Summary Key Messages FluView Activity Update LAIV Effectiveness and Vaccinatin f Children H3N2 Match and Vaccinatin Vaccine Supply Summary Key Messages This week s FluView reprt indicates

More information

National Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQ s) For PA Health & Wellness Providers

National Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQ s) For PA Health & Wellness Providers Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQ s) Fr PA Health & Wellness Prviders Questin GENERAL Why is PA Health & Wellness implementing a Medical Specialty Slutins Prgram? Answer

More information

Continuous Positive Airway Pressure (CPAP) and Respiratory Assist Devices (RADs) including Bi-Level PAP

Continuous Positive Airway Pressure (CPAP) and Respiratory Assist Devices (RADs) including Bi-Level PAP Cntinuus Psitive Airway Pressure (CPAP) and Respiratry Assist Devices (RADs), Including Bi-Level PAP Benefit Criteria t Change fr Texas Medicaid Effective March 1, 2017 Overview f Benefit Changes Benefit

More information

3903 Fair Ridge Drive, Suite 209, Fairfax, VA Harry Byrd Hwy, Suite 285, Ashburn, VA *How did you hear about our program?

3903 Fair Ridge Drive, Suite 209, Fairfax, VA Harry Byrd Hwy, Suite 285, Ashburn, VA *How did you hear about our program? 3903 Fair Ridge Drive, Suite 209, Fairfax, VA 22033 44121 Harry Byrd Hwy, Suite 285, Ashburn, VA 220147 *Hw did yu hear abut ur prgram? Patient Histry Patient Name: First Middle: Last: Address: City: State:

More information

Cancer Association of South Africa (CANSA)

Cancer Association of South Africa (CANSA) Cancer Assciatin f Suth Africa (CANSA) Fact Sheet n Lichen Planus Intrductin Lichen planus (LP) is a disease f the skin and/r mucus membranes that resembles lichen. A lichen is a cmpsite rganism that emerges

More information

Screening Questions to Ask Patients

Screening Questions to Ask Patients Screening Questins t Ask Patients 1. Have yu ever had TB (Tuberculsis)? Yes N 2. Have yu been living with anyne in the past tw years that has been diagnsed with TB? Yes N 3. Have yu ever had a Persistent

More information

Continuous Quality Improvement: Treatment Record Reviews. Third Thursday Provider Call (August 20, 2015) Wendy Bowlin, QM Administrator

Continuous Quality Improvement: Treatment Record Reviews. Third Thursday Provider Call (August 20, 2015) Wendy Bowlin, QM Administrator Cntinuus Quality Imprvement: Treatment Recrd Reviews Third Thursday Prvider Call (August 20, 2015) Wendy Bwlin, QM Administratr Gals f the Presentatin Review the findings f Treatment Recrd Review results

More information

Independent Charitable Patient Assistance Program (IPAP) Code of Ethics

Independent Charitable Patient Assistance Program (IPAP) Code of Ethics Independent Charitable Patient Assistance Prgram (IPAP) Cde f Ethics Independent charitable patient assistance prgrams (IPAPs) fcus n the needs f patients wh are insured, meet certain financial limitatin

More information

Part 1 describes the reasoning and recommendations up to node 2 of the algorithm.

Part 1 describes the reasoning and recommendations up to node 2 of the algorithm. Presented by: David Osser, MD Assciate Prfessr f Psychiatry Harvard Medical Schl Dr. Osser has n cnflicts f interest t disclse. This dcument is a summary f selected clinical pearls frm Dr. Osser s presentatin:

More information

Intravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion

Intravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment r prphylaxis. Evidence supprting this guidance is detailed belw.

More information

Package leaflet: Information for the user. Dacepton 5 mg/ml Solution for infusion Apomorphine hydrochloride hemihydrate

Package leaflet: Information for the user. Dacepton 5 mg/ml Solution for infusion Apomorphine hydrochloride hemihydrate Package leaflet: Infrmatin fr the user Daceptn 5 mg/ml Slutin fr infusin Apmrphine hydrchlride hemihydrate Read all f this leaflet carefully befre yu start using this medicine because it cntains imprtant

More information

Venom Hypersensitivity

Venom Hypersensitivity Venm Hypersensitivity Venm Allergy Large lcalised reactin ~ 10% in adults Systemic allergic reactins Up t 3% f adults Severe sting reactins in up t 1% f children In Australia, apprximately 2 fatalities

More information

Medication Guide ABSTRAL (AB-stral) CII (fentanyl) Sublingual tablets

Medication Guide ABSTRAL (AB-stral) CII (fentanyl) Sublingual tablets Medicatin Guide ABSTRAL (AB-stral) CII (fentanyl) Sublingual tablets IMPORTANT: D nt use ABSTRAL unless yu are regularly using anther piid pain medicine arund-the-clck fr at least ne week r lnger fr yur

More information

<Date> <Group> <Address1> <Address2> <City> <State> <zip> RE: 2015 Blue Physician Recognition (BPR) Program. Dear <Group>:

<Date> <Group> <Address1> <Address2> <City> <State> <zip> RE: 2015 Blue Physician Recognition (BPR) Program. Dear <Group>: Three Penn Plaza East Newark, NJ 07105-2200 HriznBlue.cm RE: 2015 Blue Physician Recgnitin (BPR) Prgram Dear : Hrizn Blue Crss Blue Shield

More information

P02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017

P02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin Revisin 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin TABLE OF CONTENTS TABLE OF CONTENTS...

More information

Thank you for committing to engage pharmacists regarding the incredible opportunity for them to prevent opioid overdose deaths by providing naloxone!

Thank you for committing to engage pharmacists regarding the incredible opportunity for them to prevent opioid overdose deaths by providing naloxone! Thank yu fr cmmitting t engage pharmacists regarding the incredible pprtunity fr them t prevent piid verdse deaths by prviding nalxne! If yu encunter cmplicated questins that yu are unable t answer, please

More information

Coronary Artery Disease (CAD): Beta Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) (NQF 0070)

Coronary Artery Disease (CAD): Beta Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) (NQF 0070) Crnary Artery Disease (CAD): Beta Blcker Therapy fr CAD Patients with Prir Mycardial Infarctin (MI) (NQF 0070) EMeasure Name Crnary Artery Disease EMeasure Id Pending (CAD): Beta Blcker Therapy fr CAD

More information

Percutaneous Nephrolithotomy (PCNL)

Percutaneous Nephrolithotomy (PCNL) Percutaneus Nephrlithtmy (PCNL) What is a percutaneus nephrlithtmy? is the mst effective f the cmmnly perfrmed prcedures fr kidney stnes. It is the best prcedure fr large and cmplex stnes. T perfrm this

More information

Top 10 Causes of Disability

Top 10 Causes of Disability Tp 10 Causes f Disability Disability can happen t anyne, f any age. Thugh sme may be the result f accidents r injuries that are unavidable, many disabilities are the result f diseases and health cnditins

More information